Use: Labeled indications
- To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with…
Full indications and usage US FDA label
1 INDICATIONS AND USAGE ZOCOR ® is indicated: To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia.
In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia.
Hypertriglyceridemia. ZOCOR is an HMG-CoA reductase inhibitor indicated: (1) To reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events.
As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies to reduce LDL-C in adults with homozygous familial hypercholesterolemia (HoFH).
As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia.
Contraindications
4 CONTRAINDICATIONS ZOCOR is contraindicated in the following conditions: Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) [see Drug Interactions (7.1)]. Concomitant use of cyclosporine, danazol or gemfibrozil [see Drug Interactions (7.1)].
Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)]. Hypersensitivity to simvastatin or any excipients in ZOCOR. Hypersensitivity reactions, including anaphylaxis, angioedema and Stevens-Johnson syndrome, have been reported [see Adverse Reactions (6.2)]. Concomitant use of strong CYP3A4 inhibitors (select azole anti-fungals, macrolide antibiotics, anti-viral medications, and nefazodone) (4, 7.1) Concomitant use of cyclosporine, danazol or gemfibrozil (4, 7.1) Acute liver failure or decompensated cirrhosis (4, 5.3) Hypersensitivity to simvastatin or any excipient in ZOCOR (4, 6.2)
US FDA labelDosing: Adult
- Important Dosage and Administration Information: (2.1)
- ZOCOR is no longer marketed in the 5 mg and 80 mg strengths. For dosing with the 5 mg strength, use another simvastatin product. Take ZOCOR orally once daily in the evening. Maximum recommended dosage is ZOCOR 40 mg once daily. An 80 mg daily dosage of ZOCOR is restricted to patients who have been taking simvastatin 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ZOCOR 40 mg daily, prescribe alternative LDL-C lowering treatment. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating, and adjust the dosage if necessary. Adults: Recommended dosage is 20 mg to 40 mg once daily. (2.2)
- Pediatric Patients Aged 10 Years and Older with HeFH: Recommended dosage is 10 mg to 40 mg once daily. (2.3)
- Patients with Severe Renal Impairment: Recommended starting dosage is simvastatin 5 mg once daily. (2.4, 8.6)
- See full prescribing information for ZOCOR dosage modifications due to drug interactions. (2.5)
2.1 Important Dosage and Administration Information
2.1 Important Dosage and Administration Information ZOCOR is no longer marketed in the 5 mg and 80 mg strengths. For dosing with the 5 mg strength, use another simvastatin product. Take ZOCOR orally once daily in the evening. The maximum recommended dosage is ZOCOR 40 mg once daily [see Dosage and Administration (2.2, 2.3)].
An 80 mg daily dosage of ZOCOR is restricted to patients who have been taking simvastatin 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions (5.1)]. If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ZOCOR 40 mg daily, prescribe alternative LDL-C-lowering treatment.
Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ZOCOR, and adjust the dosage if necessary.
2.2 Recommended Dosage in Adult Patients
2.2 Recommended Dosage in Adult Patients The recommended dosage range of ZOCOR is 20 mg to 40 mg once daily.
2.3 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HeFH
2.3 Recommended Dosage in Pediatric Patients 10 Years of Age and Older with HeFH The recommended dosage range of ZOCOR is 10 mg to 40 mg daily.
2.4 Recommended Dosage in Patients with Renal Impairment
2.4 Recommended Dosage in Patients with Renal Impairment For patients with severe renal impairment [creatinine clearance (CLcr) 15 – 29 mL/min], the recommended starting dosage of simvastatin is 5 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)]. Use another simvastatin product to initiate dosing in such patients [see Dosage and Administration (2.1)].
There are no dosage adjustment recommendations for patients with mild or moderate renal impairment.
2.5 Dosage Modifications Due to Drug Interactions
2.5 Dosage Modifications Due to Drug Interactions Concomitant use of ZOCOR with the following drugs requires dosage modification of ZOCOR [see Warnings and Precautions (5.1) and Drug Interactions (7.1)]. Patients taking Lomitapide Reduce the dosage of ZOCOR by 50%. Do not exceed ZOCOR 20 mg once daily (or 40 mg once daily for patients who have previously taken an 80 mg daily dosage of ZOCOR chronically while taking lomitapide) [see Dosage and Administration (2.1)].
Patients taking Verapamil, Diltiazem, or Dronedarone Do not exceed ZOCOR 10 mg once daily. Patients taking Amiodarone, Amlodipine, or Ranolazine Do not exceed ZOCOR 20 mg once daily.
Dosing: Altered kidney function
2.4 Recommended Dosage in Patients with Renal Impairment For patients with severe renal impairment [creatinine clearance (CLcr) 15 – 29 mL/min], the recommended starting dosage of simvastatin is 5 mg once daily [see Warnings and Precautions (5.1) and Use in Specific Populations (8.6)]. Use another simvastatin product to initiate dosing in such patients [see Dosage and Administration (2.1)]. There are no dosage adjustment recommendations for patients with mild or moderate renal impairment.
8.6 Renal Impairment Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. In patients with severe renal impairment (CLcr 15 – 29 mL/min), the recommended starting dosage is simvastatin 5 mg once daily [see Dosage and Administration (2.4), Warnings and Precautions (5.1)]. The 5 mg strength of ZOCOR is no longer marketed. Use another simvastatin product to initiate dosing in such patients.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosing: Hepatic impairment
8.7 Hepatic Impairment ZOCOR is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4), Warnings and Precautions (5.3)].
US FDA labelDosing: Pediatric
Pediatric use (US label) US FDA label
8.4 Pediatric Use The safety and effectiveness of ZOCOR as an adjunct to diet to reduce LDL-C have been established in pediatric patients 10 years of age and older with HeFH. Use of ZOCOR for this indication is based on a double-blind, placebo-controlled clinical study in 175 pediatric patients (99 boys and 76 girls at least 1 year post-menarche) 10 years of age and older with HeFH.
In this limited controlled study, there was no significant effect on growth or sexual maturation in the boys or girls, or on menstrual cycle length in girls. The safety and effectiveness of ZOCOR have not been established in pediatric patients younger than 10 years of age with HeFH or in pediatric patients with other types of hyperlipidemia (other than HeFH).
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of ZOCOR-treated patients in clinical studies 1,021 (23%) patients, 5,366 (52%) patients, and 363 (15%) patients were ≥65 years old, respectively. In Study HPS, 615 (6%) patients were ≥75 years old [see Clinical Studies (14)]. In a clinical study of patients treated with ZOCOR 80 mg daily, patients ≥65 years of age had an increased risk of myopathy, including rhabdomyolysis, compared to patients <65 years of age.
A pharmacokinetic study with ZOCOR use showed the mean plasma level of total inhibitors to be approximately 45% higher in geriatric patients between 70-78 years of age compared with patients between 18-30 years of age [see Clinical Pharmacology (12.3)]. Advanced age (≥65 years) is a risk factor for ZOCOR-associated myopathy and rhabdomyolysis.
Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving ZOCOR for the increased risk of myopathy [see Warnings and Precautions (5.1)].
Administration
2.1 Important Dosage and Administration Information ZOCOR is no longer marketed in the 5 mg and 80 mg strengths. For dosing with the 5 mg strength, use another simvastatin product. Take ZOCOR orally once daily in the evening. The maximum recommended dosage is ZOCOR 40 mg once daily [see Dosage and Administration (2.2 , 2.3) ] . An 80 mg daily dosage of ZOCOR is restricted to patients who have been taking simvastatin 80 mg daily chronically (e.g., for 12 months or more) without evidence of muscle toxicity [see Warnings and Precautions (5.1) ] . If as dose is missed, take the missed dose as soon as possible. Do not double the next dose. For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving ZOCOR 40 mg daily, prescribe alternative LDL-C-lowering treatment. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating ZOCOR, and adjust the dosage if necessary.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 5 mg, 10 mg, 20 mg, 40 mg, 80 mg
- Tablet: 10 mg, 20 mg, 40 mg, 80 mg
Registered products in the Philippines
119 products registered with the Food and Drug Administration (FDA) Philippines list Simvastatin as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products119
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
AltovastSimvastatin | 20 mg Film-Coated TabletFoil Strip x 10's (Box of 30's); Foil Strip x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Altomed Pharmaceuticals, Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1064-04 | Mar 11, 2028 | |
Asivast-10Simvastatin | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc.Importer: PhilRx Pharma Inc. | DRP-7976-01 | Feb 11, 2030 | |
Asivast-20Simvastatin | 20 mg Film-Coated TabletAlu/PVC Blister Pack of 10's (Box of 30's and 100's) | RxVAT-exempt | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc.Importer: PhilRx Pharma Inc. | DRP-7965-01 | Feb 11, 2030 | |
BuztinSimvastatin | 10 mg Film-Coated TabletFoil Strip x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1069 | Mar 11, 2028 | |
BuztinSimvastatin | 20 mg Film-Coated TabletFoil Strip x 10's (Box of 30's and 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1064 | Mar 11, 2028 | |
BuztinSimvastatin | 40 mg FIlm-Coated TabletFoil Strip x 10's (Box of 30's and 100's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Philippines | TGP Pharma, Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1368 | Feb 24, 2028 | |
BuztinSimvastatin | 80 mg Film-Coated TabletFoil Strip x 10's (Box of 30's and 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1065 | Mar 11, 2028 | |
CardiosimSimvastatin | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | The Cathay YSS Distributors Co., Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-2288-03 | Jun 28, 2028 | |
CholestadSimvastatin | 20 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Berlin Pharmaceutical Industry Co., Ltd.Thailand | Littman Drug Corporation | DR-XY44165 | Feb 9, 2030 | |
CholestadSimvastatin | 40 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Berlin Pharmaceutical Industry Co., Ltd.Thailand | Littman Drug Corporation | DR-XY44166 | Feb 9, 2030 | |
Cholestol-40Simvastatin | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. LtdIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-2288-01 | Jun 28, 2028 | |
CholestrolSimvastatin (Reformulated) | 20 mg Film-Coated TabletAlu-PVC/PVDC Blister x 10's (Box of 100's and 10's as Physician's Sample); Alu-PVC/PVDC Blister x 2's (Box of 2's as Physician's Sample) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | — | DRP-1375 | Oct 29, 2028 | |
Cholestrol (Reformulated)Simvastatin | 40 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | — | DRP-1346 | Oct 29, 2028 | |
CorvastinSimvastatin | 40 mg Film-Coated TabletAlu/Alu Foil Strip x 10's Box of 30's; Alu/Alu Foil Strip x 10's Box of 30's - Treatment Pack for DOH | RxVAT-exempt | Aurochem Pharmaceuticals (India) Pvt. LtdIndia | Endure Medical, Inc. | DR-XY43791 | Oct 16, 2029 | |
DiastatinSimvastatin | 10 mg TabletAlu/PVC Blister Amber Pack x 20’s Box of 100’s | RxVAT-exempt | Diamond Laboratories, Inc.Philippines | Rilem Pharma Corp. | DRP-7101 | Nov 12, 2027 | |
DiastatinSimvastatin | 20 mg TabletAlu/PVC Blister Amber Pack x 20’s (Box of 100’s); Alu/Amber PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7103 | Nov 12, 2027 | |
DiastatinSimvastatin | 40 mg TabletAlu/Amber PVC Blister Pack x 20’s (Box of 100’s); Alu/Amber PVC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7102 | Nov 12, 2027 | |
EcostaSimvastatin | 20 mg TabletAlu/Alu Blister Pack x10's Box of 30's | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-281 | Aug 3, 2028 | |
EcostaSimvastatin | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-280 | Aug 29, 2028 | |
Endovaz-10Simvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s and 100’s | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Limited)India | Diafarm Inc.Importer: Ambica International Corporation | DRP-5910 | Dec 19, 2029 | |
EurocorSimvastatin | 40 mg Film-Coated TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Westfield Pharmaceuticals, Inc.Trader: Euro-Health Care Exponents, Inc. | DR-XY30578 | Mar 3, 2030 | |
ForcadSimvastatin | 10 mg Film-Coated TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils, Inc. | DR-XY47963 | Apr 25, 2027 | |
ForcadSimvastatin | 20 mg Film-Coated TabletStrip Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY29327 | Jan 27, 2031 | |
ForcadSimvastatin | 40 mg Film-Coated TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY30498 | Feb 2, 2030 | |
ForcardSimvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s and 100’s | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Limited)India | Corbridge Group Phils., Inc.Importer: Ambica International Corporation | DRP-5910-02 | Dec 19, 2029 | |
LipisimSimvastatin | 40 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Gold Life Distribution Phils. Inc. | DR-XY36322 | Jul 23, 2029 | |
LipivastSimvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Celogen Pharma Pvt., Ltd.India | Endure Medical Inc. | DR-XY44215 | Feb 24, 2030 | |
LipivastSimvastatin | 40 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 50's); Alu/PVC Blister Pack x 10's (Box of 30's - Treatment Pack for DOH) | RxVAT-exempt | Celogen Pharma Pvt. Ltd.India | Endure Medical, Inc. | DR-XY45699 | Dec 13, 2031 | |
LocholSimvastatin | 40 mg Film-Coated TabletAlu/PVC blister pack x 10's (Box of 30's) | RxVAT-exempt | Siam Bheasach Co., Ltd.Thailand | MG Prime Pharmaceutical, Inc.Importer: Atlantic Pharmaceuticals, Inc. | DR-XY34666 | Jun 26, 2028 | |
MisatinSimvastatin | 40 mg Film-Coated TabletFoil Strip x 10's (Box of 30's and 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1368-04 | Feb 24, 2028 | |
MorvicorSimvastatin | 40 mg Film-Coated TabletStrip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY31815 | May 29, 2031 | |
MorvicorSimvastatin | 80 mg Film-Coated TabletAlu/Alu Blister Pack x 8's (Box of 24's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Westfield Pharmaceuticals, Inc. | DR-XY47062 | Sep 21, 2030 | |
NoneSimvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-11961-01 | May 24, 2027 | |
NoneSimvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Ltd.)India | Actimed, Inc.Importer: Ambica International Corporation | DRP-5910-01 | Dec 19, 2029 | |
NoneSimvastatin | 10 mg TabletPVC Clear Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Pascual Laboratories Inc.Philippines | Pharex Healt Corporation | DRP-7838 | Oct 7, 2029 | |
NoneSimvastatin (Reformulated) | 20 mg Film Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's and 10's as Physician's Sample) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | St. Joseph Drugstore | DRP-1375-05 | Oct 29, 2028 | |
NoneSimvastatin | 20 mg Film-Coated TabletAluminum Foil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY43406 | May 19, 2029 | |
NoneSimvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY47335 | Jul 26, 2031 | |
NoneSimvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International Corporation | DRP-11960-01 | May 24, 2027 | |
NoneSimvastatin | 20 mg Film-Coated TabletStrip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Actimed, Inc.Trader: Vamsler Phils. Incorporated | DRP-13178-01 | Feb 11, 2031 | |
NoneSimvastatin (Reformulated) | 20 mg Film-Coated TabletAlu-PVC/PVDC Blister x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-1375-03 | Oct 29, 2028 | |
NoneSimvastatin (Reformulated) | 20 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-1375-04 | Oct 29, 2028 | |
NoneSimvastatin (Reformulated) | 20 mg Film-Coated TabletAlu-PVC/PVDC Blister x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | South Star Drug | DRP-1375-07 | Oct 29, 2028 | |
NoneSimvastatin | 20 mg Film-Coated TabletAlu/Orange PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ambitech Biopharmaceuticals Inc.Importer: Nelpa Lifesciences, Inc. | DRP-4403-02 | May 2, 2028 | |
NoneSimvastatin | 40 mg Film-Coated TabletAluminum Foil Strip x 10's Box of 30's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY43405 | May 19, 2029 | |
NoneSimvastatin | 40 mg Film-Coated TabletPVC/PE/PVDC Aluminum Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | LEK S.A.Poland | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-1241-04 | Dec 8, 2026 | |
NoneSimvastatin (Reformulated) | 40 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-1346-02 | Oct 29, 2028 | |
NoneSimvastatin (Reformulated) | 40 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-1346-03 | Oct 29, 2028 | |
NoneSimvastatin | 40 mg Film-Coated TabletAlu-PVC / PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | South Star Drug | DRP-1346-04 | Oct 29, 2028 | |
NoneSimvastatin | 40 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | International Pharmaceuticals, Inc.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-2288-04 | Jun 28, 2028 | |
NoneSimvastatin | 40 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-2288-05 | Jun 28, 2028 | |
NoneSimvastatin | 40 mg TabletPVC Clear Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Pascual Laboratories Inc.Philippines | Ritemed Phils., Inc. | DRP-5935 | Oct 7, 2029 | |
NoneSimvastatin | 40 mg TabletPVC Clear Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Pascual Laboratories, Inc.Philippines | WATSONS PERSONAL CARE STORES (PHILIPPINES), INC. | DRP-5935-02 | Oct 7, 2029 | |
NoneSimvastatin | 80 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | PharmaVital Corp.Importer: Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-2289-02 | Jun 28, 2028 | |
NovovastSimvastatin | 20 mg TabletAlu/ Orange PVC Blister Pack x 10's (Box of 30's); Alu/ Orange PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | LIFESQUARE LABORATORIES, INC.Philippines | — | DRP-3685 | Oct 28, 2028 | |
NovovastSimvastatin | 40 mg Tablet | RxVAT-exempt | LifeSquare Laboratories, Inc. | — | DRP-4972 | Nov 29, 2026 | |
PhilstatSimvastatin | 10 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-7976 | Feb 11, 2030 | |
PhilstatSimvastatin | 20 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Jiangxi Xierkangtai Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc. | DRP-7965 | Feb 11, 2030 | |
QvastSimvastatin | 20 mg TabletAlu/Orange PVC Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Lifesquare Laboratories Inc.Philippines | Alman Pharmaceuticals, Inc. | DRP-3685-06 | Oct 28, 2028 | |
RavenarSimvastatin | 40 mg Film-Coated TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma, Incorporated | DR-XY30763 | May 17, 2030 | |
Saphvas-10Simvastatin | Film-Coated Tablet 10 mgAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | SAPPHIRE LIFESCIENCES PVT. LTDIndia | NELPA LIFESCIENCES, INC. | DRP-4402 | May 2, 2028 | |
Saphvas-20Simvastatin | 20 mg Film-Coated TabletAlu/Orange PVC Blister Pack x 20's (Box of 100's); Alu/Orange PVC Blister Pack x 10's (Box of 60's); Alu/Orange PVC Blister Pack x 10's (Box of 90's); Alu/Orange PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | SAPPHIRE LIFESCIENCES PVT. LTDIndia | NELPA LIFESCIENCES, INC. | DRP-4403 | May 2, 2028 | |
Simvacare 40Simvastatin | 40 mg TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Pvt. Ltd. | DRP-2288 | Jun 28, 2028 | |
Simvacare 80Simvastatin | 80 mg TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International CorporationTrader: Endurance Healthcare Ltd. | DRP-2289 | Jun 28, 2028 | |
SimvacorSimvastatin | 20 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY49334 | Feb 13, 2030 | |
SimvacorSimvastatin | 40 mg Film-Coated TabletAlu/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Y.S.P. Industries (M) Sdn. Bhd.Malaysia | Yung Shin (Philippines), Inc. | DR-XY48331 | Sep 1, 2027 | |
SimvamacSimvastatin | 20mg TabletAlu/PVC Blister Pack x 7's (Box of 28's) | RxVAT-exempt | Zhejiang Jingxin Pharmaceutical Co. Ltd.China | Intermac Pharmaceutical Inc. | DRP-12679 | Sep 22, 2027 | |
SimvasSimvastatin | 20 mg Film-Coated TabletPVC/PE/PVDC Aluminum Blister Pack X 10’s (Box of 100’s) | RxVAT-exempt | LEK S.A.Poland | TGP Pharma, Inc.Importer: Sandoz Philippines Corporation | DRP-1242-01 | Dec 8, 2026 | |
SimvasSimvastatin | 40 mg Film-Coated TabletPVC/PE/PVDC Aluminum Blister Pack X 10’s (Box of 30’s and 100’s) | RxVAT-exempt | LEK S.A.Poland | TGP Pharma, Inc.Importer: Sandoz Philippines Corporation | DRP-1241-01 | Dec 8, 2026 | |
Simvasaph-40Simvastatin | 40 mg Film-Coated TabletAlu/Orange PVC Colored Blister pack of 10's (Box of 100's); Alu/Orange PVC Colored Blister pack of 20's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-9809 | Jun 9, 2036 | |
SimvastinSimvastatin | 40 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | GEOFMAN PHARMACEUTICALSPakistan | SAHAR INTERNATIONAL TRADING INC. | DR-XY41076 | Jul 24, 2027 | |
SimvasynSimvastatin | 10 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12429 | Aug 5, 2027 | |
SimvasynSimvastatin | 20mg Film-Coated TabletsAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-13380 | Feb 10, 2028 | |
SimvasynSimvastatin | 40 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12427 | Aug 5, 2027 | |
SimvasynSimvastatin | 40 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises Inc. | DRP-16854 | Jul 18, 2030 | |
SimvasynSimvastatin | 5 mg Film-Coated TabletAlu-PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Fredun Pharmaceuticals LimitedIndia | AMB HK Enterprises, Inc.Importer: AMB HK Enterprises Inc. | DRP-12428 | Aug 5, 2027 | |
SimvogetSimvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 10's and 30's) | RxVAT-exempt | Getz Pharma Pvt. Ltd.Pakistan | Getz Pharma (Phils.), Inc. | DR-XY36119 | Aug 8, 2027 | |
SimvogetSimvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 10's and 30's) Alu/Alu Blister Pack of 1's (Box of 1's) | RxVAT-exempt | Getz Pharma (Pvt.) Ltd.Paklistan | Getz Pharma (Pvt.) Ltd. | DR-XY33735 | Jul 15, 2030 | |
SimvogetSimvastatin | 40 mg Film-Coated TabletAlu/Alu Blister Pack of 10's (Box of 10's and 30's) Alu/Alu Blister Pack of 1's (Box of 1's) (Physician Sample) | RxVAT-exempt | Getz Pharma (Pvt.) Ltd.Pakistan | Getz Pharma (Pvt.) Ltd. | DR-XY33266 | Jul 15, 2030 | |
Sistat-20Simvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Medchem International Ltd.India | Pharma-Surrey International, Inc. | DRP-1423 | Apr 15, 2028 | |
SquastatinSimvastatin | 20 mg TabletAlu/Orange PVC Blister Pack x 10's (Box of 30's); Alu/Orange PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | LifeSquare Laboratories, Inc.Philippines | Novomed Inc. | DRP-3685-05 | Oct 28, 2028 | |
UnbrandedSimvastatin | 10 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-11961 | May 24, 2032 | |
UnbrandedSimvastatin | 20 mg Film-Coated TabletAlu/PVC/PE/PVDC Blister Pack x 10’s (Box of 30’s; Box of 100’s) | RxVAT-exempt | LEK S.A.Poland | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-1242-04 | Dec 8, 2026 | |
UnbrandedSimvastatin | 20 mg Film-Coated TabletAmber PVC/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Centurion Remedies Pvt. Ltd.India | Watsons Personal Care Stores (Philippines), Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-1856-02 | Jan 20, 2029 | |
UnbrandedSimvastatin | 20mg TabletPVC Clear Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Pascual Laboratories Inc.Philippines | Ritemed Phils., Inc. | DRP-7841 | Oct 7, 2029 | |
UnbrandedSimvastatin | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY47334 | Jul 26, 2031 | |
UnbrandedSimvastatin | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-11959 | May 24, 2032 | |
VamstatSimvastatin | 20 mg Film-Coated TabletStrip Foil x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DRP-13178 | Feb 7, 2030 | |
VasitinSimvastatin | 10 mg TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker’s Laboratories Inc.Philippines | — | DRP-763 | Feb 21, 2029 | |
VastilanSimvastatin | 20 mg Film-Coated TabletAlu/Alu blister pack x 10 tablets (box of 30 tablets) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DR-XY47962 | Apr 25, 2027 | |
VastilanSimvastatin | 20 mg Film-Coated TabletAlu/Alu blister pack x 10 tablets (Box of 30 tablets) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-16083 | Apr 25, 2027 | |
VastilanSimvastatin | 40 mg Film-Coated TabletAlu/Alu blister pack x 10 tablets (box of 30 tablets) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DR-XY47961 | Apr 25, 2027 | |
VastilanSimvastatin | 40 mg Film-Coated TabletAlu / Alu blister pack x 10s (Box of 30 tablets) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Aldril Pharmaceuticals, Inc. | DRP-16075 | Apr 25, 2027 | |
VidastatSimvastatin | 20 mg Film-Coated TabletPVC/PE/PVDC Aluminum Blister Pack X 10’s (Box of 100’s) | RxVAT-exempt | LEK S.A.Poland | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-1242-03 | Dec 8, 2026 | |
VidastatSimvastatin | 40 mg Film-Coated TabletPVC/PE/PVDC Aluminum Blister Pack X 10’s (Box of 30’s) | RxVAT-exempt | LEK S.A.Poland | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-1241-03 | Dec 8, 2026 | |
VidastatSimvastatin | 5 mg Film-Coated TabletAlu/PVC/PVDC thermoforming blister pack x 10's (Box of 30's) | RxVAT-exempt | UNILAB, Inc.Philippines | — | DR-XY37054 | Nov 23, 2029 | |
VidastatSimvastatin | 80 mg Film-Coated TabletPVC/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Unilab, Inc. | DR-XY30512 | May 31, 2027 | |
Vistasaph-10Simvastatin | 10 mg Film-Coated TabletAlu/Orange PBC Blister Pack x 10's (Box of 30's and 100's) and 20's (Box of 100's) | RxVAT-exempt | Sai Parenteral Ltd.India | Nelpa Lifesciences, Inc. | DRP-18450 | Jul 13, 2031 | |
Vistasaph-20Simvastatin | 20mg Film-Coated TabletAlu/Orange PBC Blister Pack x 10's (Box of 30's, 60's, 90's and 100's) and 20's (Box of 100's) | RxVAT-exempt | Sai Parenteral Ltd.India | Nelpa Lifesciences, Inc. | DRP-18449 | Jul 13, 2031 | |
Vistasaph-40Simvastatin | 40 mg Film-Coated TabletAlu/Orange PBC Blister Pack x 10's (Box of 30's and 100's) and 20's (Box of 100's) | RxVAT-exempt | Sai Parenteral Ltd.India | Nelpa Lifesciences, Inc. | DRP-18448 | Jul 13, 2031 | |
Vistatin 10Simvastatin | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | Nelpa Lifesciences, Inc. | DRP-4402-01 | May 2, 2028 | |
VISTATIN 10Simvastatin | 10 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s); Alu/Clear PVC Blister Pack x 10’s (Box of 60’s); Alu/Clear PVC Blister Pack x 10’s (Box of 90’s); Alu/Clear PVC Blister Pack x 10’s (Box of 100’s); Alu/Clear PVC Blister Pack x 20’s (Box of 100’s) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-4402-02 | Mar 30, 2032 | |
Vistatin 20Simvastatin | 20 mg Film-Coated TabletAlu/Orange PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. LtdIndia | 777 Red Pharma Inc.Importer: Nelpa Lifesciences, Inc. | DRP-4403-01 | May 2, 2028 | |
XimvastSimvastatin | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | MICRO LABS LIMITEDIndia | ADP PHARMA CORPORATIONImporter: BROWN & BURK PHILIPPINES, INC. | DRP-281-01 | Aug 3, 2028 | |
XimvastSimvastatin | 40 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Micro Labs LimitedIndia | ADP PHARMA CORPORATIONImporter: BROWN & BURK PHILS., INC. | DRP-280-01 | Aug 29, 2028 | |
ZimvastSimvastatin | 10 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1852 | Mar 13, 2028 | |
ZimvastSimvastatin | 20 mg Film-Coated TabletAlu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1856 | Jan 20, 2029 | |
ZimvastSimvastatin | 40 mg Film-Coated TabletAlu/Amber Colored Blister Pack x 10's Box of 100's | RxVAT-exempt | Centurion Remedies Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1853 | Aug 18, 2029 | |
ZocorSimvastatin | 20 mg TabletBlister Pack x 10's (Box of 30's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Organon (Philippines) Incorporated | DRP-6241 | Jan 13, 2030 | |
Zocor HPSimvastatin | 40 mg TabletBlister Pack x 5 's (Box of 30's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Organon (Philippines) Incorporated | DRP-6243 | Feb 10, 2028 | |
(no brand name)Simvastatin | 10 mg Film Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49726 | May 18, 2031 | |
(no brand name)Simvastatin | 10 mg Film-Coated TabletBlister pack x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY27488 | Oct 22, 2027 | |
(no brand name)Simvastatin | 20 mg Film Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49725 | May 18, 2031 | |
(no brand name)Simvastatin | 20 mg Film-Coated TabletPVC/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DR-XY27487 | May 31, 2027 | |
(no brand name)Simvastatin | 20 mg Film-Coated TabletBlister pack x 10's (Box of 100's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY29267 | Jun 6, 2027 | |
(no brand name)Simvastatin | 20 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-11960 | May 24, 2027 | |
(no brand name)Simvastatin | 40 mg Film Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Phils., Inc. | DR-XY49724 | May 18, 2032 | |
(no brand name)Simvastatin | 40 mg Film-Coated TabletBlister pack x 10's (Box of 10's, 30's compliance pack, and 100's) | RxVAT-exempt | Amherst laboratories, Inc.Philippines | Trader: Ritemed Phils., Inc. | DR-XY29254 | Jun 6, 2027 | |
(no brand name)Simvastatin | 40 mg TabletAluminum Foil Strip x 10's (Box of 10's) | RxVAT-exempt | Aurochem Pharmaceuticals (I) Pvt. Ltd.India | Airlife International Trading Corporation | DRP-16795 | Jul 11, 2030 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS ZOCOR tablets: 10 mg: peach, oval tablets, marked MSD 735 on one side and plain on the other 20 mg: tan, oval tablets, marked MSD 740 on one side and plain on the other 40 mg: brick red, oval tablets, marked MSD 749 on one side and plain on the other The 5 mg and 80 mg strengths of ZOCOR are no longer marketed. Tablets: 10 mg; 20 mg; 40 mg (3) The 5 mg and 80 mg strengths of ZOCOR are no longer marketed.
Warnings/Precautions
- Myopathy and Rhabdomyolysis: Risk factors include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs, and higher ZOCOR dosage. Chinese patients may be at higher risk for myopathy. Discontinue ZOCOR if markedly elevated CK levels occur or myopathy is diagnosed or suspected. Temporarily discontinue ZOCOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing ZOCOR dosage. Instruct patients to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. (5.1, 7.1, 8.5, 8.6, 8.8)
- Immune-Mediated Necrotizing Myopathy (IMNM): Rare reports of IMNM, an autoimmune myopathy, have been reported. Discontinue ZOCOR if IMNM is suspected. (5.2)
- Hepatic Dysfunction: Increases in serum transaminases have occurred, some persistent. Rare reports of fatal and non-fatal hepatic failure have occurred. Consider testing liver enzyme before initiating therapy and as clinically indicated thereafter. If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZOCOR. (4, 5.3, 8.7)
5.1 Myopathy and Rhabdomyolysis
5.1 Myopathy and Rhabdomyolysis ZOCOR may cause myopathy and rhabdomyolysis. Acute kidney injury secondary to myoglobinuria and rare fatalities have occurred as a result of rhabdomyolysis in patients treated with statins, including ZOCOR. In clinical studies of 24,747 ZOCOR-treated patients with a median follow-up of 4 years, the incidence of myopathy, defined as unexplained muscle weakness, pain, or tenderness accompanied by creatinine kinase (CK) increases greater than ten times the upper limit of normal (10xULN), were approximately 0.03%, 0.08%, and 0.61% in patients treated with ZOCOR 20 mg, 40 mg, and 80 mg daily, respectively.
In another clinical study of 12,064 ZOCOR-treated patients (with a history of myocardial infarction) with a mean follow-up of 6.7 years, the incidences of myopathy in patients taking ZOCOR 20 mg and 80 mg daily were approximately 0.02% and 0.9%, respectively. The incidences of rhabdomyolysis (defined as myopathy with a CK >40xULN) in patients taking ZOCOR 20 mg and 80 mg daily were approximately 0% and 0.4%, respectively [see Adverse Reactions (6.1)].
Risk Factors for Myopathy Risk factors for myopathy include age 65 years or greater, uncontrolled hypothyroidism, renal impairment, concomitant use with certain other drugs (including other lipid-lowering therapies), and higher ZOCOR dosage; Chinese patients on ZOCOR may be at higher risk for myopathy [see Contraindications (4), Drug Interactions (7.1), and Use in Specific Populations (8.8)]. The risk of myopathy is increased by elevated plasma levels of simvastatin and simvastatin acid.
The risk is also greater in patients taking an 80 mg daily dosage of ZOCOR compared with patients taking lower ZOCOR dosages and compared with patients using other statins with similar or greater LDL-C-lowering efficacy [see Adverse Reactions (6.1)]. Steps to Prevent or Reduce the Risk of Myopathy and Rhabdomyolysis The concomitant use of strong CYP3A4 inhibitors with ZOCOR is contraindicated.
If short-term treatment with strong CYP3A4 inhibitors is required, temporarily suspend ZOCOR during the duration of strong CYP3A4 inhibitor treatment. The concomitant use of ZOCOR with gemfibrozil, cyclosporine, or danazol is also contraindicated [see Contraindications (4) and Drug Interactions (7.1)]. ZOCOR dosage modifications are recommended for patients taking lomitapide, verapamil, diltiazem, dronedarone, amiodarone, amlodipine or ranolazine [see Dosage and Administration (2.5)].
ZOCOR use should be temporarily suspended in patients taking daptomycin. Lipid modifying doses (≥1 gram/day) of niacin, fibrates, colchicine, and grapefruit juice may also increase the risk of myopathy and rhabdomyolysis [see Drug Interactions (7.1)]. Use the 80 mg daily dosage of ZOCOR only in patients who have been taking simvastatin 80 mg daily chronically without evidence of muscle toxicity [see Dosage and Administration (2.1)].
If patients treated with an 80 mg daily dosage of ZOCOR are prescribed an interacting drug that increases the risk for myopathy and rhabdomyolysis, switch to an alternate statin [see Drug Interactions (7.1)]. Discontinue ZOCOR if markedly elevated CK levels occur or if myopathy is either diagnosed or suspected. Muscle symptoms and CK increases may resolve if ZOCOR is discontinued.
Temporarily discontinue ZOCOR in patients experiencing an acute or serious condition at high risk of developing renal failure secondary to rhabdomyolysis, e.g., sepsis; shock; severe hypovolemia; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; or uncontrolled epilepsy. Inform patients of the risk of myopathy and rhabdomyolysis when starting or increasing the ZOCOR dosage and advise patients receiving an 80 mg daily dosage of ZOCOR of the increased risk of myopathy and rhabdomyolysis.
Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness, particularly if accompanied by malaise or fever.
5.2 Immune-Mediated Necrotizing Myopathy
5.2 Immune-Mediated Necrotizing Myopathy There have been rare reports of immune-mediated necrotizing myopathy (IMNM), an autoimmune myopathy, associated with statin use, including reports of recurrence when the same or a different statin was administered. IMNM is characterized by proximal muscle weakness and elevated serum creatine kinase that persist despite discontinuation of statin treatment; positive anti-HMG CoA reductase antibody; muscle biopsy showing necrotizing myopathy without significant inflammation; and improvement with immunosuppressive agents.
Additional neuromuscular and serologic testing may be necessary. Treatment with immunosuppressive agents may be required. Discontinue ZOCOR if IMNM is suspected.
5.3 Hepatic Dysfunction
5.3 Hepatic Dysfunction Increases in serum transaminases have been reported with use of ZOCOR [see Adverse Reactions (6.1)]. In most cases, these changes appeared soon after initiation, were transient, were not accompanied by symptoms, and resolved or improved on continued therapy or after a brief interruption in therapy.
Persistent increases to more than 3xULN in serum transaminases have occurred in approximately 1% of patients receiving ZOCOR in clinical studies. Marked persistent increases of hepatic transaminases have also occurred with ZOCOR. There have been rare postmarketing reports of fatal and non-fatal hepatic failure in patients taking statins, including ZOCOR.
Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury. Consider liver enzyme testing before ZOCOR initiation and when clinically indicated thereafter. ZOCOR is contraindicated in patients with acute liver failure or decompensated cirrhosis [see Contraindications (4)].
If serious hepatic injury with clinical symptoms and/or hyperbilirubinemia or jaundice occurs, promptly discontinue ZOCOR.
5.4 Increases in HbA1c and Fasting Serum Glucose Levels
5.4 Increases in HbA1c and Fasting Serum Glucose Levels Increases in HbA1c and fasting serum glucose levels have been reported with statins, including ZOCOR. Optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices.
Drug interactions
- See full prescribing information for details regarding concomitant use of ZOCOR with other drugs or grapefruit juice that increase the risk of myopathy and rhabdomyolysis. (2.5, 7.1)
- Coumarin Anticoagulants: Obtain INR before ZOCOR initiation and monitor INR during ZOCOR dosage initiation or adjustment. (7.2)
- Digoxin: During ZOCOR initiation, monitor digoxin levels. (7.2)
7.1 Drug
7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with ZOCOR ZOCOR is a substrate of CYP3A4 and of the transport protein OATP1B1. ZOCOR exposure can be significantly increased with concomitant administration of inhibitors of CYP3A4 and OATP1B1. Table 2 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with ZOCOR and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].
Table 2: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with ZOCOR Strong CYP3A4 inhibitors Clinical Impact: Simvastatin is a substrate of CYP3A4. Concomitant use of strong CYP3A4 inhibitors with ZOCOR increases simvastatin exposure and increases the risk of myopathy and rhabdomyolysis, particularly with higher ZOCOR dosages.
Intervention: Concomitant use of strong CYP3A4 inhibitors with ZOCOR is contraindicated [see Contraindications (4)]. If treatment with a CYP3A4 inhibitor is unavoidable, suspend ZOCOR during the course of strong CYP3A4 inhibitor treatment. Examples: Select azole anti-fungals (e.g., itraconazole, ketoconazole, posaconazole, and voriconazole), select macrolide antibiotics (e.g., erythromycin and clarithromycin), select HIV protease inhibitors (e.g., nelfinavir, ritonavir, and darunavir/ritonavir), select HCV protease inhibitors (e.g., boceprevir and telaprevir), cobicistat-containing products, and nefazodone.
Cyclosporine, Danazol, or Gemfibrozil Clinical Impact: The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine, danazol, or gemfibrozil with ZOCOR. Gemfibrozil may cause myopathy when given alone. Intervention: Concomitant use of cyclosporine, danazol, or gemfibrozil with ZOCOR is contraindicated [see Contraindications (4)].
Amiodarone, Dronedarone, Ranolazine, or Calcium Channel Blockers Clinical Impact: The risk of myopathy and rhabdomyolysis is increased by concomitant use of amiodarone, dronedarone, ranolazine, or calcium channel blockers with ZOCOR. Intervention: For patients taking verapamil, diltiazem, or dronedarone, do not exceed ZOCOR 10 mg daily.
For patients taking amiodarone, amlodipine, or ranolazine, do not exceed ZOCOR 20 mg daily [see Dosage and Administration (2.5)]. Lomitapide Clinical Impact: Simvastatin exposure is approximately doubled with concomitant use of lomitapide and the risk of myopathy and rhabdomyolysis is increased. Intervention: Reduce the dose of ZOCOR by 50% if initiating lomitapide.
Do not exceed ZOCOR 20 mg daily (or ZOCOR 40 mg daily for patients who have previously taken an 80 mg daily dosage of ZOCOR chronically) while taking lomitapide [see Dosage and Administration (2.1, 2.5)]. Daptomycin Clinical Impact: Cases of rhabdomyolysis have been reported with simvastatin administered with daptomycin.
Both ZOCOR and daptomycin can cause myopathy and rhabdomyolysis when given alone and the risk of myopathy and rhabdomyolysis may be increased by coadministration. Intervention: If treatment with daptomycin is required, consider temporarily suspending ZOCOR during the course of daptomycin treatment. Niacin Clinical Impact: Cases of myopathy and rhabdomyolysis have been observed with concomitant use of lipid modifying dosages of niacin-containing products (≥1 gram/day niacin) with ZOCOR.
The risk of myopathy is greater in Chinese patients. In a clinical study (median follow-up 3.9 years) of patients at high risk of CVD and with well-controlled LDL-C levels on simvastatin 40 mg/day with or without ezetimibe 10 mg/day, there was no incremental benefit on cardiovascular outcomes with the addition of lipid-modifying doses of niacin.
Intervention: Concomitant use of ZOCOR with lipid-modifying dosages of niacin is not recommended in Chinese patients [see Use in Specific Populations (8.8)]. For non-Chinese patients, consider if the benefit of using lipid-modifying doses of niacin concomitantly with ZOCOR outweighs the increased risk of myopathy and rhabdomyolysis.
If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. Fibrates (other than Gemfibrozil) Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with ZOCOR.
Intervention: Consider if the benefit of using fibrates concomitantly with ZOCOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with ZOCOR.
Intervention: Consider if the benefit of using colchicine concomitantly with ZOCOR outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. Grapefruit Juice Clinical Impact: Grapefruit juice can raise the plasma levels of simvastatin and may increase the risk of myopathy and rhabdomyolysis.
Intervention: Avoid grapefruit juice when taking ZOCOR.
7.2 ZOCOR Effects on Other Drugs
7.2 ZOCOR Effects on Other Drugs Table 3 presents ZOCOR’s effect on other drugs and instructions for preventing or managing them. Table 3: ZOCOR Effects on Other Drugs Coumarin Anticoagulants Clinical Impact: ZOCOR may potentiate the effect of coumarin anticoagulants and increase the INR. The concomitant use of ZOCOR (20 to 40 mg) and coumarin anticoagulants increased the INR from a baseline of 1.7 to 1.8 in healthy subjects and from 2.6 to 3.4 in patients with hyperlipidemia.
There are postmarketing reports of clinically evident bleeding and/or increased INR in patients taking concomitant statins and warfarin. Intervention: In patients taking coumarin anticoagulants, obtain an INR before starting ZOCOR and frequently enough after initiation, dose titration, or discontinuation to ensure that no significant alteration in INR occurs.
Once the INR is stable, monitor INR at regularly recommended intervals. Digoxin Clinical Impact: Concomitant use of digoxin with ZOCOR may result in elevated plasma digoxin concentrations [see Clinical Pharmacology (12.3)]. Intervention: Monitor digoxin levels in patients taking digoxin when ZOCOR is initiated.
Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label
Elimination Metabolism Simvastatin is metabolized by CYP3A4.
Drug Interaction Studies Simvastatin acid is a substrate of the transport protein OATP1B1.
Concomitant administration of inhibitors of the transport protein OATP1B1 and/or CYP3A4 may lead to increased exposure of simvastatin acid.
Cyclosporine has been shown to increase the AUC of statins; although the mechanism is not fully understood, the increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4 and/or OATP1B1 [see Drug Interactions (7) ] .
Simvastatin is not an inhibitor of CYP3A4 and is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.
( 7.2 ) 7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with ZOCOR ZOCOR is a substrate of CYP3A4 and of the transport protein OATP1B1.
ZOCOR exposure can be significantly increased with concomitant administration of inhibitors of CYP3A4 and OATP1B1.
Table 2: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with ZOCOR Strong CYP3A4 inhibitors Clinical Impact: Simvastatin is a substrate of CYP3A4.
Adverse reactions
- The following important adverse reactions are described below and elsewhere in the labeling: Myopathy and Rhabdomyolysis [see Warnings and Precautions (5.1)] Immune-Mediated Necrotizing Myopathy [see Warnings and Precautions (5.2)] Hepatic Dysfunction [see Warnings and Precautions (5.3)] Increases in HbA1c and Fasting Serum Glucose Levels [see Warnings and Precautions (5.4)] Most common adverse reactions (incidence ≥5%) are upper respiratory infection, headache, abdominal pain, constipation, and nausea. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. In clinical studies, 2,423 adult patients were exposed to ZOCOR with a median duration of follow-up of approximately 18 months.
The most commonly reported adverse reactions (incidence ≥5%) in these ZOCOR clinical studies were: upper respiratory infections (9%), headache (7%), abdominal pain (7%), constipation (7%), and nausea (5%). Overall, 1.4% of patients discontinued ZOCOR due to adverse reactions. The most common adverse reactions that led to discontinuation were: gastrointestinal disorders (0.5%), myalgia (0.1%), and arthralgia (0.1%).
In a Cardiovascular Outcomes Study (the Scandinavian Simvastatin Survival Study [Study 4S]), adult patients (age range 35-71 years, 19% women, 100% Caucasians) were treated with 20-40 mg per day of ZOCOR or placebo over a median of 5.4 years [see Clinical Studies (14)]; adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 1. Table 1: Adverse Reactions Reported ≥2% of Patients Treated with ZOCOR and Greater than Placebo in Study 4S % Placebo (N = 2,223) % ZOCOR (N = 2,221) Bronchitis 6.3
6.6 Abdominal
6.6 Abdominal pain 5.8 5.9 Atrial fibrillation 5.1 5.7 Gastritis 3.9 4.9 Eczema 3.0 4.5 Vertigo 4.2 4.5 Diabetes mellitus 3.6 4.2 Insomnia 3.8 4.0 Myalgia 3.2 3.7 Urinary tract infection 3.1 3.2 Edema/swelling 2.3 2.7 Headache 2.1 2.5 Sinusitis 1.8 2.3 Constipation 1.6 2.2 Myopathy/Rhabdomyolysis In clinical studies with a median follow-up of at least 4 years, in which 24,747 patients received ZOCOR, the incidence of myopathy (defined as unexplained muscle weakness, pain, or tenderness accompanied by CK increases greater than 10xULN) was approximately 0.03%, 0.08%, and 0.61% for the ZOCOR 20 mg, 40 mg, and 80 mg daily groups, respectively. In a clinical outcomes study in which 12,064 adult patients with a history of myocardial infarction were treated with ZOCOR (mean follow-up 6.7 years), the incidence of myopathy (defined as unexplained muscle weakness or pain with a serum CK >10x [1200 U/L] ULN) in patients taking ZOCOR 20 mg and 80 mg daily was approximately 0.02% and 0.9%, respectively.
The incidence of rhabdomyolysis (defined as myopathy with a CK >40xULN) in patients on ZOCOR 20 mg and 80 mg daily was approximately 0% and 0.4%, respectively. The incidence of myopathy and rhabdomyolysis were highest during the first year and then decreased during the subsequent years of treatment. In another clinical outcomes study in which 10,269 adult patients were treated with ZOCOR 40 mg per day (mean follow-up of 5 years), the incidence of myopathy/rhabdomyolysis was <0.1% in patients treated with ZOCOR.
Elevations in Liver Enzyme Tests Moderate (less than 3xULN) elevations of serum transaminases have been reported with use of ZOCOR. Persistent increases to more than 3xULN in serum transaminases have occurred in approximately 1% of patients receiving ZOCOR in clinical studies. Marked persistent increases of hepatic transaminases have occurred with ZOCOR.
Elevated alkaline phosphatase and γ-glutamyl transpeptidase have also been reported. In Study 4S, with a median follow-up of 5.4 years, 1,986 adult patients were treated with ZOCOR 20 mg once daily, of whom 37% titrated to 40 mg once daily. The percentage of patients with one or more occurrences of transaminase elevations to >3xULN was 0.7% in patients taking ZOCOR compared with 0.6% in patients taking placebo.
Elevated transaminases leading to discontinuation of study treatment occurred in 0.4% of patients taking ZOCOR and 0.2% of patients taking placebo. The majority of elevated transaminases leading to treatment discontinuation occurred within in the first year. Adverse Reactions in Pediatric Patients with Heterozygous Familial Hypercholesterolemia In a 48-week clinical study in pediatric patients 10 years of age and older (43% female, 97.7% Caucasians, 1.7% Hispanics, 0.6% Multiracial) with HeFH (n=175), treated with placebo or ZOCOR (10-40 mg daily), the most common adverse reactions were upper respiratory infection, headache, abdominal pain, and nausea [see Use in Specific Populations (8.4) and Clinical Studies (14)].
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ZOCOR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Body as whole: fever, chills, malaise, asthenia Blood and Lymphatic System Disorders: anemia, thrombocytopenia, leukopenia, hemolytic anemia, positive ANA, ESR increase, eosinophilia Gastrointestinal Disorders: pancreatitis, vomiting Hepatic and Pancreatic Disorders: hepatitis/jaundice, fatal and non-fatal hepatic failure Immune System Disorders: hypersensitivity syndrome including: anaphylaxis, angioedema, lupus erythematous-like syndrome, dermatomyositis, vasculitis Musculoskeletal and Connective Tissue Disorders: muscle cramps, immune-mediated necrotizing myopathy, polymyalgia rheumatica, arthritis Nervous System Disorders: dizziness, depression, paresthesia, peripheral neuropathy.
Rare reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, confusion) associated with statin use. Cognitive impairment was generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks).
There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered. Skin and Subcutaneous Tissue Disorders: pruritus, alopecia, a variety of skin changes (e.g., nodules, discoloration, dryness of skin/mucous membranes, changes to hair/nails), purpura, lichen planus, urticaria, photosensitivity, flushing, toxic epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome Respiratory and Thoracic: interstitial lung disease, dyspnea Reproductive System Disorders: erectile dysfunction
Adverse reaction frequency tables (US label) US FDA label
| % Placebo (N = 2,223) | % ZOCOR (N = 2,221) | |
|---|---|---|
| Bronchitis | 6.3 | 6.6 |
| Abdominal pain | 5.8 | 5.9 |
| Atrial fibrillation | 5.1 | 5.7 |
| Gastritis | 3.9 | 4.9 |
| Eczema | 3.0 | 4.5 |
| Vertigo | 4.2 | 4.5 |
| Diabetes mellitus | 3.6 | 4.2 |
| Insomnia | 3.8 | 4.0 |
| Myalgia | 3.2 | 3.7 |
| Urinary tract infection | 3.1 | 3.2 |
| Edema/swelling | 2.3 | 2.7 |
| Headache | 2.1 | 2.5 |
| Sinusitis | 1.8 | 2.3 |
| Constipation | 1.6 | 2.2 |
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary Discontinue ZOCOR when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. ZOCOR decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, ZOCOR may cause fetal harm when administered to pregnant patients based on the mechanism of action [see Clinical Pharmacology (12.1)].
In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations.
Published data from prospective and retrospective observational cohort studies with ZOCOR use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (see Data). In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered simvastatin during the period of organogenesis at doses that resulted in 2.5 and 2 times, respectively, the human exposure at the maximum recommended human dosage of 80 mg/day, based on body surface area (mg/m 2) (see Data).
The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods.
The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders.
In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births.
Animal Data Simvastatin was given to pregnant rats at doses of 6.25, 12.5 and 25 mg/kg/day (0.6 times, 1.3 times, and 2.5 times, respectively, the maximum recommended dosage of 80 mg/day when normalized to body surface area) from gestation days 6-17 and to pregnant rabbits from gestation days 6-18 at doses of 2.5, 5, and 10 mg/kg/day (0.5 times, 1 times, and 2 times, respectively, the maximum recommended dosage of 80 mg/day when normalized to body surface area). For both species, there was no evidence of maternal toxicity or embryolethality.
In rats, mean fetal body weights in the 25 mg/kg/day group were decreased 5.4%. Similar fetal body weight effects were not observed in rabbits. Simvastatin doses of 6.25, 12.5 and 25 mg/kg/day (0.6 times, 1.3 times, and 2.5 times, respectively, the maximum recommended dosage of 80 mg/day when normalized to body surface area) were given to pregnant rats from gestation day 15 to lactation day 21.
Slight decreases in maternal body weight gain and pup postnatal day 0 weight were observed in the 25 mg/kg/day dose group. Mean body weight gain of pups during lactation was slightly decreased at doses ≥12.5 mg/kg/day. Post weaning weight, behavior, reproductive performance and fertility of the offspring were not affected at any dose tested.
Placental transfer of simvastatin was not evaluated in rats or rabbits. However, it has been shown that other drugs in this class cross the placenta.
Mechanism of action
12.1 Mechanism of Action Simvastatin is a prodrug and is hydrolyzed to its active β-hydroxyacid form, simvastatin acid, after administration. Simvastatin acid and its metabolites are inhibitors of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a precursor of cholesterol.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Inhibition of HMG-CoA reductase by simvastatin acid accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of ZOCOR is usually achieved by 4 weeks and is maintained after that.
Pharmacokinetics
Excretion Following an oral dose of 14 C-labeled simvastatin, 13% of the dose was excreted in urine and 60% in feces.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Simvastatin is a lactone that is readily hydrolyzed in vivo to the corresponding β-hydroxyacid. Pharmacokinetics (PK) of simvastatin and its metabolites was originally characterized using inhibition of HMG-CoA reductase activity following base hydrolysis of plasma samples, as specific bioanalytical methods were not available.
Inhibition of the enzyme activity (equivalent to the level of total inhibitors) represented the combination of activities in plasma following administration of simvastatin from both active (simvastatin acid and its metabolites) and latent forms (simvastatin and its metabolites) after conversion to the active forms in the presence of base. Absorption Following an oral dose of 14 C-labeled simvastatin, plasma concentrations of total radioactivity (simvastatin plus 14 C-metabolites) peaked at 4 hours and declined rapidly to about 10% of peak by 12 hours postdose.
Since simvastatin undergoes extensive first-pass extraction in the liver, the availability of simvastatin to the general circulation is low (<5%). PK, assessed as area under the concentrations of total inhibitors – time curve, was apparently linear with doses up to 120 mg. Effect of Food The plasma profile of total inhibitors concentration was not affected when simvastatin was administered with low fat meal.
Distribution Both simvastatin and its β-hydroxyacid metabolite are highly bound (approximately 95%) to human plasma proteins. Elimination Metabolism Simvastatin is metabolized by CYP3A4. The major active metabolites of simvastatin present in human plasma are simvastatin acid and its 6′-hydroxy, 6′-hydroxymethyl, and 6′-exomethylene derivatives.
Peak plasma concentrations of both active and total inhibitors were attained within 1.3 to 2.4 hours postdose. Excretion Following an oral dose of 14 C-labeled simvastatin, 13% of the dose was excreted in urine and 60% in feces. Specific Populations Geriatric Patients In a study including 16 geriatric patients between 70 and 78 years of age who received ZOCOR 40 mg/day, the mean plasma level of total inhibitors was increased approximately 45% compared with 18 patients between 18-30 years of age [see Use in Specific Populations (8.5)].
Drug Interaction Studies Simvastatin acid is a substrate of the transport protein OATP1B1. Concomitant administration of inhibitors of the transport protein OATP1B1 and/or CYP3A4 may lead to increased exposure of simvastatin acid. Cyclosporine has been shown to increase the AUC of statins; although the mechanism is not fully understood, the increase in AUC for simvastatin acid is presumably due, in part, to inhibition of CYP3A4 and/or OATP1B1 [see Drug Interactions (7)].
Table 4 displays the effect of coadministered drugs or grapefruit juice on simvastatin systemic exposure [see Drug Interactions (7)]. Table 4: Effect of Coadministered Drugs or Grapefruit Juice on Simvastatin Systemic Exposure Coadministered Drug or Grapefruit Juice Dosing of Coadministered Drug or Grapefruit Juice Dosing of Simvastatin Geometric Mean Ratio (Ratio Results based on a chemical assay except results with propranolol as indicated. with / without coadministered drug) No Effect = 1.00 AUC C max Telithromycin Results could be representative of the following CYP3A4 inhibitors: ketoconazole, erythromycin, clarithromycin, HIV protease inhibitors, and nefazodone. 200 mg QD for 4 days 80 mg simvastatin acid Simvastatin acid refers to the β-hydroxyacid of simvastatin. simvastatin 12 8.9 15 5.3 Nelfinavir 1250 mg BID for 14 days 20 mg QD for 28 days simvastatin acid simvastatin 6 6.2 Itraconazole 200 mg QD for 4 days 80 mg simvastatin acid simvastatin 13.1 13.1 Posaconazole 100 mg (oral suspension) QD for 13 days 40 mg simvastatin acid simvastatin 7.3 10.3 9.2 9.4 200 mg (oral suspension) QD for 13 days 40 mg simvastatin acid simvastatin 8.5 10.6 9.5 11.4 Gemfibrozil 600 mg BID for 3 days 40 mg simvastatin acid simvastatin 2.85 1.35 2.18 0.91 Grapefruit Juice The effect of amounts of grapefruit juice between those used in these two studies on simvastatin pharmacokinetics has not been studied.
(high dose) 200 mL of double-strength TID Double-strength: one can of frozen concentrate diluted with one can of water. Grapefruit juice was administered TID for 2 days, and 200 mL together with single dose simvastatin and 30 and 90 minutes following single dose simvastatin on Day 3. 60 mg single dose simvastatin acid simvastatin 7 16 Grapefruit Juice (low dose) 8 oz (about 237 mL) of single-strength Single-strength: one can of frozen concentrate diluted with 3 cans of water.
Grapefruit juice was administered with breakfast for 3 days, and simvastatin was administered in the evening on Day 3. 20 mg single dose simvastatin acid simvastatin 1.3 1.9 Verapamil SR 240 mg QD Days 1-7 then 240 mg BID on Days 8-10 80 mg on Day 10 simvastatin acid simvastatin 2.3 2.5 2.4 2.1 Diltiazem 120 mg BID for 10 days 80 mg on Day 10 simvastatin acid simvastatin 2.69 3.10 2.69 2.88 Diltiazem 120 mg BID for 14 days 20 mg on Day 14 simvastatin 4.6 3.6 Dronedarone 400 mg BID for 14 days 40 mg QD for 14 days simvastatin acid simvastatin 1.96 3.90 2.14 3.75 Amiodarone 400 mg QD for 3 days 40 mg on Day 3 simvastatin acid simvastatin 1.75 1.76 1.72 1.79 Amlodipine 10 mg QD × 10 days 80 mg on Day 10 simvastatin acid simvastatin 1.58 1.77 1.56 1.47 Ranolazine SR 1000 mg BID for 7 days 80 mg on Day 1 and Days 6-9 simvastatin acid simvastatin 2.26 1.86 2.28 1.75 Lomitapide 60 mg QD for 7 days 40 mg single dose simvastatin acid simvastatin 1.7 2 1.6 2 Lomitapide 10 mg QD for 7 days 20 mg single dose simvastatin acid simvastatin 1.4 1.6 1.4 1.7 Fenofibrate 160 mg QD × 14 days 80 mg QD on Days 8-14 simvastatin acid simvastatin 0.64 0.89 0.89 0.83 Niacin extended-release 2 g single dose 20 mg single dose simvastatin acid simvastatin 1.6 1.4 1.84 1.08 Propranolol 80 mg single dose 80 mg single dose total inhibitor 0.79 ↓ from 33.6 to 21.1 ng∙eq/mL active inhibitor 0.79 ↓ from 7.0 to 4.7 ng∙eq/mL ZOCOR’s Effect on the Pharmacokinetics of Other Drugs In a study of 12 healthy volunteers, simvastatin at the 80-mg dose had no effect on the metabolism of the probe cytochrome P450 isoform 3A4 (CYP3A4) substrates midazolam and erythromycin. Simvastatin is not an inhibitor of CYP3A4 and is not expected to affect the plasma levels of other drugs metabolized by CYP3A4.
Coadministration of simvastatin (40 mg QD for 10 days) resulted in an increase in the maximum mean levels of cardioactive digoxin (given as a single 0.4 mg dose on day 10) by approximately 0.3 ng/mL [see Drug Interactions (7.2)].
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Simvastatin 20 mg Tablet | ₱0.79–₱5.50Reference ₱1.40 | per tablet | DPRI procurement range |
| Simvastatin 40 mg Tablet | ₱2.00–₱8.00Reference ₱3.50 | per tablet | DPRI procurement range |
| 20 mg tablet | ₱6.50 | per tablet | PhilHealth GAMOT fixed fee |
| 40 mg tablet | ₱10.00 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Simvastatin |
| PNF listing | Oral: 20 mg and 40 mg tabletRestrictions: Specific expertise, diagnostic precision, or special equipment required for proper use (PNF code 1) |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. ZOCOR · Organon LLC [US FDA-approved label, version 11, March 28, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8f55d5de-5a4f-4a39-8c84-c53976dd6af9
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .